Hydrocortisone in Severe Community-Acquired Pneumonia

In this randomized trial, hydrocortisone treatment decreased mortality among patients with severe community-acquired pneumonia in the ICU.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 388; no. 21; pp. 1931 - 1941
Main Authors Dequin, Pierre-François, Meziani, Ferhat, Quenot, Jean-Pierre, Kamel, Toufik, Ricard, Jean-Damien, Badie, Julio, Reignier, Jean, Heming, Nicholas, Plantefève, Gaëtan, Souweine, Bertrand, Voiriot, Guillaume, Colin, Gwenhaël, Frat, Jean-Pierre, Mira, Jean-Paul, Barbarot, Nicolas, François, Bruno, Louis, Guillaume, Gibot, Sébastien, Guitton, Christophe, Giacardi, Christophe, Hraiech, Sami, Vimeux, Sylvie, L’Her, Erwan, Faure, Henri, Herbrecht, Jean-Etienne, Bouisse, Camille, Joret, Aurélie, Terzi, Nicolas, Gacouin, Arnaud, Quentin, Charlotte, Jourdain, Mercé, Leclerc, Marie, Coffre, Carine, Bourgoin, Hélène, Lengellé, Céline, Caille-Fénérol, Caroline, Giraudeau, Bruno, Le Gouge, Amélie
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 25.05.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In this randomized trial, hydrocortisone treatment decreased mortality among patients with severe community-acquired pneumonia in the ICU.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2215145